NCT03436615 - A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum | Biotech Hunter

Enrollment

256

Participants

Timeline

Start Date

January 24, 2018

Primary Completion Date

November 3, 2018

Study Completion Date

November 3, 2018

Conditions

Molluscum Contagiosum

Interventions

DRUG

SB206 4%

Twice daily

DRUG

SB206 8%

Twice daily

DRUG

SB206 12%

Once or twice daily

DRUG

Placebo

Once or twice daily

Trial Locations (18)

23294

Premier Site# 267, Richmond

29414

Premier Site# 259, Charleston

29464

Premier Site# 255, Mt. Pleasant

30263

Premier Site# 116, Newnan

33172

Premier Site# 264, Doral

40241

Premier Site# 117, Louisville

46256

Premier Site# 251, Indianapolis

66215

Premier Site# 253, Lenexa

73071

Premier Site# 252, Norman

77004

Premier Site# 131, Houston

77030

Premier Site# 167, Houston

78218

Premier Site# 224, San Antonio

80233

Premier Site# 257, Thornton

84124

Premier Site# 256, Salt Lake City

85255

Premier Site# 266, Scottsdale

89129

Premier Site# 182, Las Vegas

92701

Premier Site# 260, Santa Ana

97030

Premier Site# 237, Gresham